论文部分内容阅读
在70年代后期,由于单克隆抗体和重组DNA技术的应用,干扰素生产及其纯度的难题得到解决,研究数据足以说明一种干扰素包含一种生物学功能的固有认识是不正确的,干扰素是调节性蛋白质大家族中的众多成员。近10年来,干扰素在实验室试验观察的同时已试用于临床治疗传染性疾病和恶性肿瘤。人类干扰素蛋白质产物由165～187个氨基酸构成,分子量为17～25 kD,可分为3种主要型——α、β、γ。α干扰素有许多亚型,功能上几乎没有什么差异,单一α亚型和自然产生的混合α亚型的临床活性完全相同。目前临床应用有效的干扰素有α干扰素亚型合剂、重组α_2干扰素、自然和重组β干扰素以及重组γ干扰
In the late 1970s, due to the use of monoclonal antibodies and recombinant DNA technology, the problem of interferon production and its purity was resolved and the data provided were sufficient to show that an inherent recognition that interferon contained a biological function was incorrect and disrupted Su is a member of a large family of regulatory proteins. For nearly 10 years, interferon has been tested in clinical trials for the treatment of infectious diseases and malignancies, as well as laboratory tests. Human interferon protein products from 165 to 187 amino acids, molecular weight of 17 ~ 25 kD, can be divided into three main types - α, β, γ. There are many subtypes of interferon alpha, with little difference in function, and the clinical activity of a single alpha subtype and a naturally occurring mixed alpha subtype are exactly the same. At present, interferon effective in clinical application is interferon alpha subtype, recombinant alpha 2 interferon, natural and recombinant beta interferon, and recombinant gamma interferon